Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis

A Novel Molecular Target for Breast Cancer Prevention and Treatment

“…To support this, RARy transcriptionally active AHPN derivatives and analogues were also reported to inhibit growth and induce apoptosis (28,48,49). Other reports present data strongly suggesting an RAR-independent pathway, such as growth inhibition and apoptosis of retinoid-resistant cancer cells (13,14,21,27,42,44,50). 3 Our results support the latter by showing that MM 11453, although unable to activate retinoid receptors on a reporter with the efficacy of standard retinoids or AHPN, strongly inhibited growth and induced apoptosis in retinoid-resistant cancer cell lines.…”

“…Increasing evidence, including retinoid-resistant cancer cell growth inhibition (13,27), suggests that AHPN action is independent of retinoid receptors (21,44). Cell counting and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays were conducted to show that MM 11453 inhibited growth similarly.…”

Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells

“…Their structures are very similar and their ability to transactivate RARE-reporter gene constructs is comparable with CD271 being more potent on RARb and equipotent on RARg (Sun et al, 1997a). Recently, it was suggested that a 95 kD protein may mediate the eect of CD437 on apoptosis (Fontana et al, 2000). It would be of interest to determine whether CD271 has lower anity for this protein than CD437 that could explain its lower potency as an apoptosis inducer.…”

SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule–mediated nuclear factor-κB activation, c-Fos/c-Jun expression, and cellular apoptosis

“…Reagents 3-Cl-AHPC was synthesized as described previously (28,29). [5,5′-3 H 2 ]AHPN was obtained from Vitrax.…”

“…Binding Assay Binding assays were done as we have previously published (27,29). In the immunoprecipitation binding assays, specific primary antibodies (1 μg) were added in 500 μL binding buffer containing nuclear extracts with labeled and nonlabeled ligands and incubated at 4°C for 2 h and binding was assessed (27).…”